XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of
an investigational drug. Phase I studies also try to define the appropriate dose of the
investigational drug to use for further studies. "Investigational" means that the drug is
still being studied and that research doctors are trying to find out more about it. It also
means the FDA has not approved the drug for your type of cancer.
Cabozantanib (XL184) is a new drug that is being developed to treat cancer. The study drug
cabozantinib works by inhibiting several different proteins which are believed to be involved
in multiple myeloma growth, its ability to spread, and its ability to form new blood vessels.
This drug has been used in other research studies and information from those other research
studies suggests that this drug may help to slow or stop disease growth to bones and prevent
cancer growth.
In this research study, we are looking to see how effective cabozantanib is in slowing or
stopping disease growth to the bones as well as preventing your cancer from worsening. We are
also looking for the highest dose of cabozantinib that can be given safely to patients who
have multiple myeloma with bone disease.